As of Oct 21
| -0.01 / -0.79%|
The 2 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +140.00% increase from the last price of 1.25.
The current consensus among 3 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.